Zanubrutinib + Obinutuzumab + Sonrotoclax for Mantle Cell Lymphoma

This trial tests a new combination of three drugs—zanubrutinib, obinutuzumab, and sonrotoclax—to determine their effectiveness in treating mantle cell lymphoma (MCL), a type of blood cancer. The goal is to assess whether this combination effectively controls the disease. Suitable candidates for this trial include individuals diagnosed with MCL who face challenges with standard treatments due to other health conditions, such as heart or lung problems. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Previous studies have found the combination of zanubrutinib, obinutuzumab, and sonrotoclax manageable for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Most side effects were mild to moderate, with diarrhea occurring in about 37% of patients.

Zanubrutinib, in particular, has demonstrated a good safety record for patients new to mantle cell lymphoma (MCL) treatment, causing fewer heart-related side effects compared to similar treatments. Although some serious side effects occurred, they were less common.

Researchers are excited about the combination of Zanubrutinib, Obinutuzumab, and Sonrotoclax for treating Mantle Cell Lymphoma because it offers a novel approach compared to existing treatments. While traditional therapies often rely on chemotherapy, this treatment harnesses the power of targeted therapies. Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that blocks signals that help cancer cells survive and grow. Obinutuzumab is a monoclonal antibody that targets CD20 on B-cells, enhancing the body's immune response against cancer cells. Sonrotoclax is designed to inhibit a protein that helps cancer cells evade death, promoting their destruction. This multi-target strategy has the potential to be more effective and have fewer side effects than conventional chemotherapy.

Research has shown that the combination of zanubrutinib, obinutuzumab, and sonrotoclax, which participants in this trial will receive, may be promising for treating mantle cell lymphoma (MCL). In earlier studies, many patients who received this treatment had a strong response, with 60% achieving a complete response, meaning no detectable cancer in their blood. Additionally, many patients experienced deep remission, indicating a significant impact of the treatment. This combination also proved effective in other conditions like chronic lymphocytic leukemia (CLL), where it led to quick and deep remissions. The success in these areas suggests potential effectiveness for MCL as well.³⁵⁶⁷⁸